Caption Management’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.12M Buy
184,100
+134,100
+268% +$4.69M 0.03% 488
2026
Q1
$1.92M Buy
50,000
+39,500
+376% +$1.46M 0.01% 831
2025
Q4
$373K Sell
10,500
-369,500
-97% -$10.4M ﹤0.01% 1290
2025
Q3
$5.46M Sell
380,000
-928,600
-71% -$11M 0.04% 463
2025
Q2
$9.4M Buy
+1,308,600
New +$7.25M 0.1% 223
2024
Q2
Sell
-39,800
Closed -$267K 1208
2024
Q1
$267K Buy
+39,800
New +$246K ﹤0.01% 965

Other funds holding COGT

Caption Management's COGT Position: Q2 2026 in Review

Caption Management sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 20,000 shares — an estimated $700K sold.

Caption Management first reported a position in COGT in Q2 2022 and held it in 6 quarters. The position peaked at $3.14M in Q2 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Caption Management reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 20,000 Cogent Biosciences shares in Q2 2026, an estimated $700K.
  • Caption Management first reported a position in Cogent Biosciences in Q2 2022 and held it in 6 quarters.
  • Caption Management's Cogent Biosciences position peaked at $3.14M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.